Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 03, 2026
AMC Networks (AMCX) +6% Gains on Netflix Deal for The Walking Dead Universe

AMC Networks (AMCX) +6% Gains on Netflix Deal for The Walking Dead Universe

Key Takeaways

  • AMC Networks shares have gained approximately 6% over the last 30 days, moving from around $10.26 in early July to roughly $10.90 in early August, driven largely by a landmark licensing agreement with Netflix.
  • The company announced a five-year, $500 million co-exclusive global streaming deal with NFLX for the entire The Walking Dead universe, covering seven series and 371 episodes.
  • Q2 2026 results reflected ongoing revenue pressure — consolidated revenue fell 9% year-over-year to $547.5 million — but management called the quarter the expected trough for adjusted operating income.
  • Full-year 2026 guidance was raised materially: consolidated revenue of $2.40–$2.45 billion, adjusted operating income of $410–$420 million, and free cash flow of roughly $220 million.
  • Wall Street remains cautious, with a consensus "Reduce" rating and an average 12-month price target of $8.50, though several analysts raised targets following the Netflix announcement.
  • The stock hit a 52-week high of $11.66 on July 31 following the Q2 report and licensing news before settling near $10.90 in subsequent sessions.

Current Market Snapshot

AMC Networks, now operating under the brand name AMC Global Media, has seen its stock trade in a volatile range between roughly $9.30 and $11.66 over the past several weeks. After spending much of June and early July in the $9.30–$10.30 zone, shares surged more than 15% on July 31 when the company released second-quarter results alongside the Netflix licensing pact. The stock moved above its 200-day moving average of approximately $8.52 in mid-July and has stayed there since, reflecting a shift in sentiment. Even so, AMCX continues to trade at a modest price-to-sales multiple of approximately 0.25, which tells me the market is still skeptical about the durability of the legacy linear television business even as streaming and licensing show renewed momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AMC Networks (AMCX) Business Overview and Competitive Position

AMC Networks is a global entertainment company that develops, produces, and distributes premium content across television and streaming platforms. Its portfolio includes linear cable networks — AMC, WE tv, BBC America, IFC, and SundanceTV — as well as a growing suite of targeted direct-to-consumer streaming services: AMC+, Acorn TV, Shudder, Sundance Now, ALLBLK, HIDIVE, and All Reality. The company also operates AMC Studios, the in-house production arm behind major franchises including The Walking Dead and the Anne Rice Immortal Universe. Following international divestitures completed in 2023, domestic operations now account for nearly 90% of total revenue. The company differentiates itself by owning a deep library of original intellectual property and by catering to passionate niche audiences rather than competing head-to-head with large-scale general-entertainment streaming platforms. Investors track AMCX closely as a bellwether for how mid-tier media companies can monetize legacy content libraries in an increasingly streaming-first landscape.

Recent Developments Driving AMCX

The single most consequential event in the last 30 days was the July 30 disclosure of a five-year, $500 million global co-exclusive streaming licensing agreement with NFLX covering the entire The Walking Dead franchise — all seven series and 371 episodes. Under the terms, AMC Networks expects to recognize roughly $445 million in total revenue over the deal's life, with $200 million to $225 million recognized in both 2026 and 2027. The original Walking Dead series is also set to return to AMC+ in January 2027 for the first time.

The licensing news overshadowed otherwise weak second-quarter financial results. Consolidated revenue declined 9% year-over-year to $547.5 million, missing analyst estimates, while the company reported an adjusted loss of $0.28 per share. Domestic subscription revenue dropped 5% as a 17% decline in affiliate fees more than offset 6% streaming revenue growth. Advertising revenue was also pressured, though digital advertising grew 44% compared to the prior-year period.

On the analyst front, Morgan Stanley raised its price target to $10 from $7 while maintaining an Underweight rating, citing the deal's validation of AMC's intellectual property alongside ongoing concerns about subscriber growth and secular industry headwinds. Wells Fargo lifted its target to $11 from $10 with an Equal Weight rating. The broader analyst consensus remains cautious, with two Sell and two Hold ratings and an average price target of $8.50.

On the balance sheet, AMC repaid its remaining Term Loan A and terminated its credit facility during the quarter. The company ended Q2 with approximately $464 million in cash against roughly $1.3 billion in net debt, with approximately 75% of total debt not maturing until July 2032. From what I see, this debt profile provides some breathing room as the company executes on its new licensing strategy.

2026 Outlook and What Investors Should Watch

The raised full-year 2026 guidance — $2.40 billion to $2.45 billion in revenue, $410 million to $420 million in adjusted operating income, and roughly $220 million in free cash flow — sets a higher bar for the second half of the year. Management expects both revenue and profitability to improve from Q2 levels as licensing revenue from the Netflix deal begins flowing and distribution agreements with major pay-TV providers such as CMCSA and GOOG-owned YouTube take effect.

Key factors to monitor include the pace of affiliate revenue decline in the domestic linear business, the trajectory of streaming subscriber acquisition following the company's decision to stop reporting subscriber figures quarterly, and the sustainability of digital advertising growth. The company's ability to execute on content licensing beyond The Walking Dead will also be critical — investors will look for evidence that AMC can replicate its IP monetization playbook across other franchises, including the Anne Rice universe. Macroeconomic considerations such as advertising market health, consumer discretionary spending trends, and competitive dynamics in streaming remain important external variables. With net leverage at 4.1 times and a concentrated franchise portfolio, AMC's margin for operational missteps remains limited heading into 2027.

Using Tickeron’s Trending AI Robots

In my own research, I occasionally review Tickeron’s Trending AI Robots page to see how top-performing bots are positioned across various tickers. It offers a curated look at algorithmic strategies that can help put data-driven context around names like AMCX without adding emotional bias to the process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AMCX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for AMCX turns positive, indicating new upward trend

AMCX saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AMCX just turned positive on July 31, 2026. Looking at past instances where AMCX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

AMCX moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AMCX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 180 cases where AMCX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AMCX moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AMCX broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMCX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.543) is normal, around the industry mean (20.878). P/E Ratio (11.522) is within average values for comparable stocks, (105.936). Projected Growth (PEG Ratio) (0.545) is also within normal values, averaging (14.151). AMCX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.267) is also within normal values, averaging (2.993).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.22B. The market cap for tickers in the group ranges from 134 to 325.79B. NFLX holds the highest valuation in this group at 325.79B. The lowest valued company is LRDG at 134.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was 2%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 11%. SPHR experienced the highest price growth at 14%, while GAIA experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 49
Price Growth Rating: 53
SMR Rating: 84
Profit Risk Rating: 76
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
AMCX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

an operator of cable television networks through its subsidiaries

Industry MoviesEntertainment

Profile
Details
Industry
Cable Or Satellite TV
Address
11 Penn Plaza
Phone
N/A
Employees
1738
Web
https://www.amcglobalmedia.com
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.